{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:11Z","timestamp":1790310371949,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ctrv.2016.09.005","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T19:27:19Z","timestamp":1473708439000},"page":"118-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge"],"prefix":"10.1016","volume":"50","author":[{"given":"Tejaswi","family":"Kandula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun V.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.09.005_b0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ctrv.2010.02.003","article-title":"Epidemiology of childhood cancer","volume":"36","author":"Kaatsch","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2016.09.005_b0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1055-9965.EPI-14-1418","article-title":"Survivors of childhood cancer in the United States: prevalence and burden of morbidity","volume":"24","author":"Phillips","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology."},{"key":"10.1016\/j.ctrv.2016.09.005_b0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2016.09.005_b0020","unstructured":"Kmet LM, Lee RC, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research; 2004."},{"key":"10.1016\/j.ctrv.2016.09.005_b0025","first-page":"548","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"69","author":"Ebell","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ctrv.2016.09.005_b0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/mus.24647","article-title":"Vincristine-induced neuropathy: A typical electrophysiological patterns in children","volume":"52","author":"Courtemanche","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ctrv.2016.09.005_b0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1017\/S0317167100018461","article-title":"Chemotherapy-induced peripheral neuropathy among paediatric oncology patients","volume":"41","author":"Purser","year":"2014","journal-title":"Can J Neurol Sci - Le Journal Canadien des Sciences Neurologiques"},{"key":"10.1016\/j.ctrv.2016.09.005_b0040","first-page":"39","article-title":"Vincristine induced neurotoxicity: Study of 75 cases","volume":"3","author":"Arzanian","year":"2009","journal-title":"Iran J Child Neurol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0045","first-page":"351","article-title":"Electrophysiological consequences of vincristine contained chemotherapy in children: A cohort study","volume":"7","author":"Toopchizadeh","year":"2009","journal-title":"J Pediatr Neurol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0050","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/pbc.23039","article-title":"Neuropathic pain during treatment for childhood acute lymphoblastic leukemia","volume":"57","author":"Anghelescu","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jns.12114","article-title":"Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"20","author":"Lavoie Smith","year":"2015","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.ctrv.2016.09.005_b0060","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF02759902","article-title":"Vincristine induced cranial polyneuropathy","volume":"73","author":"Bay","year":"2006","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.ctrv.2016.09.005_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jop.1988.4.117","article-title":"Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma","volume":"4","author":"Teichmann","year":"1988","journal-title":"J Ocul Pharmacol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/pbc.22882","article-title":"Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children\u2019s Oncology Group","volume":"57","author":"Langholz","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/mpo.1084","article-title":"Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials","volume":"36","author":"Harila-Saari","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0887-8994(95)00191-3","article-title":"Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve","volume":"13","author":"Vainionpaa","year":"1995","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pbc.10375","article-title":"Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide\/carboplatin\/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil","volume":"42","author":"Fagundes Loss","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0095","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pbc.22544","article-title":"A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children\u2019s Oncology Group study","volume":"55","author":"Beaty","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2010.09.015","article-title":"Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study","volume":"47","author":"Geoerger","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0105","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1200\/JCO.2008.16.7585","article-title":"Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies","volume":"26","author":"Geoerger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0110","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1200\/JCO.2006.08.2388","article-title":"Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors","volume":"25","author":"Spunt","year":"2007","journal-title":"J Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2016.09.005_b0115","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22241","article-title":"Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study","volume":"107","author":"Fouladi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/pbc.24278","article-title":"A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors","volume":"60","author":"Macy","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00043426-200307000-00008","article-title":"Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study","volume":"25","author":"Hayashi","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0130","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/pbc.21310","article-title":"A phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children\u2019s Oncology Group study","volume":"50","author":"Horton","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0135","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1200\/JCO.1993.11.12.2324","article-title":"Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study","volume":"11","author":"Hurwitz","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0140","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1054\/bjoc.2000.1637","article-title":"Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study","volume":"84","author":"Doz","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0145","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pbc.21820","article-title":"Pediatric Oncology Group s. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376)","volume":"52","author":"Geller","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0150","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.1997.15.4.1538","article-title":"Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children\u2019s Cancer Group trial","volume":"15","author":"Blaney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0155","first-page":"733","article-title":"Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children\u2019s Cancer Group trial","volume":"5","author":"Seibel","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.09.005_b0160","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/1471-2407-14-622","article-title":"A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors","volume":"14","author":"Yoon","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0165","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/cncr.21779","article-title":"Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the children\u2019s oncology group","volume":"106","author":"Zwerdling","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0170","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/1078-0432.CCR-09-1906","article-title":"Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children\u2019s oncology group","volume":"16","author":"Jacobs","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.09.005_b0175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2008.17.6644","article-title":"Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors","volume":"27","author":"Widemann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0180","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1200\/JCO.2004.12.185","article-title":"Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children\u2019s Oncology Group study (ADVL0015)","volume":"22","author":"Blaney","year":"2004","journal-title":"J Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2016.09.005_b0185","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/pbc.25117","article-title":"A phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"61","author":"Horton","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0190","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pbc.24271","article-title":"A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children\u2019s Oncology Group phase I consortium study (ADVL0916)","volume":"60","author":"Muscal","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0195","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2016.09.005_b0200","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/MIB.0000000000000437","article-title":"Effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: Pilot randomized clinical trial","volume":"21","author":"Lazzerini","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ctrv.2016.09.005_b0205","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pediatrneurol.2007.11.004","article-title":"Childhood thalidomide neuropathy: a clinical and neurophysiologic study","volume":"38","author":"Priolo","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0210","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nmd.2004.10.005","article-title":"Thalidomide neuropathy in childhood","volume":"15","author":"Fleming","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ctrv.2016.09.005_b0215","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0883073813491829","article-title":"Vincristine-induced neuropathy in childhood ALL (Acute Lymphoblastic Leukemia) survivors: Prevalence and electrophysiological characteristics","volume":"29","author":"Jain","year":"2014","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0220","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1529-8027.2009.00230.x","article-title":"Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia","volume":"14","author":"Ramchandren","year":"2009","journal-title":"J Peripher Nerv Syst: JPNS"},{"key":"10.1016\/j.ctrv.2016.09.005_b0225","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<200::AID-CNCR25>3.0.CO;2-5","article-title":"Nerve lesions after therapy for childhood acute lymphoblastic leukemia","volume":"82","author":"Harila-Saari","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0230","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.10503","article-title":"Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia","volume":"94","author":"Lehtinen","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13577149878055","article-title":"Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas","volume":"2","author":"Earl","year":"1998","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2016.09.005_b0240","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cncr.26337","article-title":"Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses","volume":"118","author":"Ness","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0245","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.apmr.2013.03.009","article-title":"Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study","volume":"94","author":"Ness","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.ctrv.2016.09.005_b0250","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1200\/JCO.2012.47.8081","article-title":"Deficits in physical function among young childhood cancer survivors","volume":"31","author":"Hoffman","year":"2013","journal-title":"J Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2016.09.005_b0255","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pbc.21325","article-title":"Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer","volume":"50","author":"Hartman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0260","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1096-911X(199612)27:6<551::AID-MPO8>3.0.CO;2-K","article-title":"Fine motor and handwriting problems after treatment for childhood acute lymphoblastic leukemia","volume":"27","author":"Reinders-Messelink","year":"1996","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0265","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/ptj\/85.8.782","article-title":"Proficiency of balance in children and youth who have had acute lymphoblastic leukemia","volume":"85","author":"Wright","year":"2005","journal-title":"Phys Ther"},{"key":"10.1016\/j.ctrv.2016.09.005_b0270","unstructured":"NCI. Common terminology criteria for adverse events v4.03; 2010."},{"key":"10.1016\/j.ctrv.2016.09.005_b0275","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00520-013-1981-6","article-title":"Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children","volume":"22","author":"Gilchrist","year":"2014","journal-title":"Support Care Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0280","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00520-012-1591-8","article-title":"The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers","volume":"21","author":"Gilchrist","year":"2013","journal-title":"Support Care Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0285","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1097\/NCC.0b013e318299ad23","article-title":"Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"36","author":"Lavoie Smith","year":"2013","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.ctrv.2016.09.005_b0290","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/pbc.25384","article-title":"Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer","volume":"62","author":"Bradfield","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0295","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2016.09.005_b0300","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mpo.1216","article-title":"Analysis of handwriting of children during treatment for acute lymphoblastic leukemia","volume":"37","author":"Reinders-Messelink","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0305","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pbc.21045","article-title":"A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies","volume":"49","author":"Gilheeney","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0310","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.ctrv.2016.09.005_b0315","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/08880018.2011.624163","article-title":"Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia","volume":"29","author":"Teusink","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0320","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.1996.14.3.935","article-title":"Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine","volume":"14","author":"Weintraub","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/1817-1745.154358","article-title":"Guillain-Barre syndrome in acute lymphoblastic leukemia: Causal or coincidental","volume":"10","author":"Bhushan","year":"2015","journal-title":"J Pediatr Neurosci"},{"key":"10.1016\/j.ctrv.2016.09.005_b0330","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0883073811428379","article-title":"Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia","volume":"27","author":"Brigo","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0335","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/pgs.14.68","article-title":"Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia","volume":"15","author":"Ceppi","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ctrv.2016.09.005_b0340","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/mpo.10105","article-title":"Vincristine neurotoxicity in the presence of hereditary neuropathy","volume":"40","author":"Trobaugh-Lotrario","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0345","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/MPH.0b013e3181e9038d","article-title":"A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study","volume":"32","author":"Mokhtar","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0350","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12098-010-0096-z","article-title":"Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy","volume":"77","author":"Akbayram","year":"2010","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.ctrv.2016.09.005_b0355","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/j.ctrv.2016.09.005_b0360","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Postma","year":"1998","journal-title":"Ann Oncol: Official Journal of the European Society for Medical Oncology\/ESMO"},{"issue":"Suppl 11","key":"10.1016\/j.ctrv.2016.09.005_b0365","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1002\/acr.20635","article-title":"Measures of pediatric function: Child Health Assessment Questionnaire (C-HAQ), Juvenile Arthritis Functional Assessment Scale (JAFAS), Pediatric Outcomes Data Collection Instrument (PODCI), and Activities Scale for Kids (ASK)","volume":"63","author":"Klepper","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ctrv.2016.09.005_b0370","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0375","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ana.24265","article-title":"Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy","volume":"76","author":"Beutler","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ctrv.2016.09.005_b0380","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pbc.24784","article-title":"Vitamin B12 deficiency: the great masquerader","volume":"61","author":"Dobrozsi","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2016.09.005_b0385","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2016.09.005_b0390","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/jns.12116","article-title":"Systematic review of exercise for Charcot-Marie-Tooth disease","volume":"20","author":"Sman","year":"2015","journal-title":"J Peripher Nerv Syst: JPNS"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T05:45:41Z","timestamp":1718775941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216300846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":78,"alternative-id":["S0305737216300846"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726781956.793529719","asserted-by":"object"}]},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}